Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Reproductive System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Genitourinary System Neoplasm
Reproductive System Neoplasm

Cancer Family

Reproductive System Neoplasm

CI-CAN-00000338Explore in graph →

Non-malignant3,042 active trials38 approved drugs197 evidence items

NCIt: C3674

Overview
Statistics
Survival
Genomics65
Variants & evidence197
Drugs58
Trials13672
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (625)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 501–525 of 625 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
· JAMA · 2012 · PMID 22274685 · validated civic_curation pubmed
EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
· Br J Cancer · 2011 · PMID 21730982 · validated civic_curation pubmed
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
· Science · 2005 · PMID 16254181 · validated civic_curation pubmed
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
· Oncogene · 2012 · PMID 22139083 · validated civic_curation pubmed
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
· Gynecol Oncol · 2012 · PMID 22112610 · validated civic_curation pubmed
mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
· Clin Cancer Res · 2006 · PMID 16467099 · validated civic_curation pubmed
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.

Showing 501–525 of 625 publications

← Previous
1
…
20
21
22
…
25
Next →

· Oncotarget · 2016 · PMID 26625204 · validated civic_curation pubmed

Elevated expression of RIT1 correlates with poor prognosis in endometrial cancer.

· Int J Clin Exp Pathol · 2015 · PMID 26617739 · validated civic_curation pubmed

Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.

· PLoS One · 2014 · PMID 24587245 · validated civic_curation pubmed

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

· N Engl J Med · 2014 · PMID 25184630 · validated civic_curation pubmed

Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.

· Cancer · 2014 · PMID 24166148 · validated civic_curation pubmed

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.

· Gynecol Oncol · 2011 · PMID 21920589 · validated civic_curation pubmed

Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.

· Int J Cancer · 2016 · PMID 26891277 · validated civic_curation pubmed

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

· Eur Urol · 2013 · PMID 23582881 · validated civic_curation pubmed

Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study.

· Target Oncol · 2013 · PMID 23238879 · validated civic_curation pubmed

Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer.

· J Clin Oncol · 2013 · PMID 23569316 · validated civic_curation pubmed

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.

· Clin Cancer Res · 2014 · PMID 24240112 · validated civic_curation pubmed

Prognostic value of Ki-67 for prostate cancer death in a conservatively managed cohort.

· Br J Cancer · 2013 · PMID 23329234 · validated civic_curation pubmed

Toward the molecular dissection of peritoneal pseudomyxoma.

· Ann Oncol · 2016 · PMID 27502722 · validated civic_curation pubmed

Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.

· J Ovarian Res · 2016 · PMID 27209210 · validated civic_curation pubmed

Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.

· Tumour Biol · 2015 · PMID 25544710 · validated civic_curation pubmed

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

· Gynecol Oncol · 2016 · PMID 26740259 · validated civic_curation pubmed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

· Lancet Oncol · 2014 · PMID 25218906 · validated civic_curation pubmed

The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.

· PLoS One · 2015 · PMID 26422378 · validated civic_curation pubmed

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

· Lancet Oncol · 2011 · PMID 21862407 · validated civic_curation pubmed